MacroGenics Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 0.8% | 443.2% | 23.2% | 26.1% | 38.3% | 31.0% | 54.4% | 48.6% | 18.4% | 28.7% | 54.0% | 142.2% | 49.6% | |
| 99.2% | -343.2% | 76.8% | 73.9% | 61.7% | 69.0% | 45.6% | 51.4% | 81.6% | 71.3% | 46.0% | -42.2% | 50.4% | |
| 289.8% | 441.7% | 505.6% | 479.1% | 36.6% | 219.3% | 287.5% | 174.8% | 42.4% | 78.3% | 160.2% | 118.1% | 80.7% | |
| 119.4% | 117.2% | 161.6% | 133.6% | 12.7% | 156.9% | 81.2% | 41.8% | 13.6% | 22.4% | 46.7% | 24.1% | 21.9% | |
| 440.6% | 117.2% | 667.2% | 612.7% | 12.7% | 367.0% | 368.7% | 216.7% | 56.0% | 100.7% | 207.0% | 142.2% | 102.6% | |
| -341.5% | -460.4% | -590.4% | -538.9% | 48.9% | -298.0% | -323.1% | -165.3% | 25.6% | -29.3% | -161.0% | -42.2% | -24.3% | |
| 0.0% | 26.7% | 12.4% | 0.1% | 0.0% | 0.1% | 0.7% | 3.6% | 4.6% | 10.4% | 23.5% | 13.4% | 10.1% | |
| 168.8% | -429.8% | -573.3% | -515.6% | 50.9% | -81.7% | -311.1% | -162.5% | 23.1% | -36.2% | -177.0% | -212.1% | -62.3% | |
| -18.8% | 30.0% | 19.7% | – | -1.7% | 5.3% | – | 0.5% | – | -1.9% | – | -271.6% | – | |
| 168.8% | -429.8% | -573.3% | -515.6% | 50.9% | -87.0% | -311.1% | -163.0% | 23.1% | -34.3% | -177.0% | 59.4% | -8.7% | |
| 187.6% | -412.1% | -540.6% | -498.7% | 52.5% | -70.2% | -297.0% | -150.3% | 30.1% | -21.7% | -145.4% | -196.6% | -48.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.